{"id":"NCT03875092","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475-407/KEYNOTE-407)-China Extension Study","officialTitle":"A Randomized, Double-Blind, Phase III Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in First Line Metastatic Squamous Non-small Cell Lung Cancer Subjects (KEYNOTE-407)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-04-21","primaryCompletion":"2020-09-30","completion":"2023-09-14","firstPosted":"2019-03-14","resultsPosted":"2021-10-20","lastUpdate":"2024-10-01"},"enrollment":125,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Non-small Cell Lung Cancer"],"interventions":[{"type":"BIOLOGICAL","name":"Pembrolizumab","otherNames":["MK-3475","KEYTRUDA速"]},{"type":"DRUG","name":"Paclitaxel","otherNames":["TAXOL速"]},{"type":"DRUG","name":"Carboplatin","otherNames":["PARAPLATIN速"]},{"type":"DRUG","name":"Saline placebo for pembrolizumab","otherNames":[]}],"arms":[{"label":"Pembrolizumab + Chemotherapy","type":"EXPERIMENTAL"},{"label":"Chemotherapy","type":"ACTIVE_COMPARATOR"}],"summary":"In this China extension study, carboplatin and paclitaxel with or without pembrolizumab (MK-3475, KEYTRUDA速) will be administered to Chinese adults with first line metastatic squamous non-small cell lung cancer (NSCLC).\n\nThe primary hypotheses are that treatment with pembrolizumab prolongs: 1) Progression-free Survival (PFS) by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) as assessed by a blinded central imaging vendor compared to placebo, and 2) Overall Survival (OS) in Chinese participants.\n\nAfter analysis of interim results was conducted, the protocol was amended (Amendment 5) to allow participants the option to discontinue placebo in the control arm and to switch to pembrolizumab in the event of documented progressive disease as assessed by central review.","primaryOutcome":{"measure":"Progression-free Survival (PFS) as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)","timeFrame":"Up to approximately 33 months","effectByArm":[{"arm":"Pembrolizumab + Chemotherapy","deltaMin":8.3,"sd":null},{"arm":"Chemotherapy","deltaMin":4.2,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":9,"exclusionCount":21},"locations":{"siteCount":1,"countries":["China"]},"refs":{"pmids":["34661177","37465924"],"seeAlso":["https://www.merckclinicaltrials.com"]},"adverseEventsSummary":{"seriousAny":{"events":35,"n":65},"commonTop":["Anaemia","Neutrophil count decreased","White blood cell count decreased","Alopecia","Hypoaesthesia"]}}